FIELD: biotechnology.
SUBSTANCE: following is described: a group of inventions including a compound, a pharmaceutical composition for the treatment or prevention of a disease or condition that is mediated or maintained by the activity of CYP11B2, including the above compound, and a method of treating or preventing a disease or condition that is mediated or maintained by the activity of CYP11B2.
EFFECT: invention expands the arsenal of agents characterized by high efficiency in inhibiting the activity of human cytochrome 11B2 (CYP11B2).
26 cl, 2 tbl, 33 ex
Title | Year | Author | Number |
---|---|---|---|
HUMAN ALDOSTERONE SYNTHASE (CYP11B2) INHIBITORS | 2023 |
|
RU2824362C1 |
HUMAN CYTOCHROME 11B2 INHIBITORS | 2021 |
|
RU2783521C1 |
HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
(AZA)INDOLE-, BENZOTHIOPHENE- AND BENZOFURAN-3-SULPHONAMIDES | 2017 |
|
RU2767904C2 |
PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
PHARMACEUTICAL AGENT CONTAINING INHIBITOR OF SODIUM-DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2740008C2 |
APOPTOSIS-INDUCING AGENTS | 2018 |
|
RU2782469C2 |
AMINOPYRAZOLE DERIVATIVE | 2010 |
|
RU2580543C9 |
PHARMACEUTICAL PRODUCT CONTAINING INHIBITOR OF SODIUM DEPENDENT PHOSPHATE CARRIER | 2015 |
|
RU2811864C1 |
ACTIVIN RECEPTOR-LIKE KINASE INHIBITORS | 2018 |
|
RU2788628C2 |
Authors
Dates
2024-01-16—Published
2022-11-10—Filed